Openfund

CORDIS · ONCOSCREEN

A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways

Code
ONCOSCREEN
Programme
HORIZON
Call
HORIZON-MISS-2021-CANCER-02-01
Status
SIGNED
Period
2023-01-01 – 2026-12-31
Total cost (whole consortium)12 972 076 €
EU contribution (whole consortium)12 972 076 €
EU contribution to Bulgarian participants511 625 €

Official data · CORDIS · synced 2026-10-17 10:16 · official record

Participants

OrganisationsRoleCountryGrant
EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIScoordinatorEL1 006 628 €
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYparticipantIL909 450 €
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZparticipantDE777 500 €
MEDIZINISCHE UNIVERSITAT GRAZparticipantAT695 375 €
FIRALISparticipantFR691 500 €
EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTONparticipantEL623 250 €
ROSENBAUM CONSULTINGparticipantBG511 625 €
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXISparticipantEL495 750 €
UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEINparticipantDE441 830 €
INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPEparticipantPT439 750 €
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETASparticipantLT420 000 €
VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V.participantBE408 310 €
TILBURG UNIVERSITY- UNIVERSITEIT VAN TILBURGparticipantNL351 500 €
UNIVERSIDADE DO MINHOparticipantPT329 975 €
SCIENTIFIC ACADEMY FOR SERVICE TECHNOLOGY EVparticipantDE329 350 €
AINIGMA TECHNOLOGIESparticipantBE298 750 €
INNOVATION SPRINTparticipantBE278 250 €
INSTITUTUL ONCOLOGIC PROF. DR. ALEXANDRU TRESTIOREANU BUCURESTIparticipantRO268 750 €
KONNEKT ABLE TECHNOLOGIES LIMITEDparticipantIE265 000 €
TIMELEXparticipantBE247 188 €
UNIVERSIDAD DE LA RIOJAparticipantES240 000 €
CATALINK LIMITEDparticipantCY239 875 €
EY ADVISORY SPAparticipantIT228 125 €
GIE AXAparticipantFR220 625 €
CARR COMMUNICATIONS LIMITEDparticipantIE211 250 €
YPOURGEIO YGEIASparticipantEL207 500 €
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASparticipantES196 625 €
UNIVERSITE MARIE ET LOUIS PASTEURparticipantFR182 977 €
BEIA CONSULT INTERNATIONAL SRLparticipantRO182 250 €
GENIKO NOSOKOMEIO ELENA VENIZELOU -ALEXANDRAparticipantEL178 125 €
PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJAparticipantLT143 750 €
LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJAparticipantLT130 184 €
EUROPACOLON PORTUGAL- ASSOCIACAO DE LUTA CONTRA O CANCRO DO INTESTINOparticipantPT115 000 €
FUNDATIA YOUTH CANCER EUROPEparticipantRO105 750 €
EUROPAISCHE VEREINIGUNG DER GASTROINTESTINALEN ONKOLOGIE(EUROPEAN SOCIETY OF DIGESTIVE ONCOLOGY - ESDO)participantAT99 875 €
LOUWEN ROGIERparticipantNL99 688 €
VOOGD SANNEparticipantNL99 688 €
ELLINIKI ETAIREIA OGKOLOGIAS PEPTIKOUparticipantEL92 625 €
FAKULTNA NEMOCNICA S POLIKLINIKOU F.D. ROOSEVELTA BANSKA BYSTRICAparticipantSK86 618 €
Delta Health Care S.R.LparticipantRO68 750 €
MEDIZINISCHE UNIVERSITAT INNSBRUCKparticipantAT47 068 €
ASSOCIATION GERCORparticipantFR6 000 €
UNIVERSITAET zu LUEBECKthird partyDE0 €

Description

With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease. ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising. Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed. The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.

Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).